Arcturus Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-7.53 Insider Own2.30% Shs Outstand26.38M Perf Week27.07%
Market Cap379.29M Forward P/E- EPS next Y-2.12 Insider Trans-3.32% Shs Float22.75M Perf Month-34.40%
Income-198.50M PEG- EPS next Q-1.84 Inst Own75.90% Short Float13.41% Perf Quarter-32.28%
Sales15.50M P/S24.47 EPS this Y-117.80% Inst Trans5.44% Short Ratio4.65 Perf Half Y-55.65%
Book/sh7.00 P/B2.37 EPS next Y82.90% ROA-49.10% Target Price56.09 Perf Year-43.70%
Cash/sh13.97 P/C1.19 EPS next 5Y- ROE-81.20% 52W Range12.12 - 65.00 Perf YTD-55.23%
Dividend- P/FCF- EPS past 5Y-58.50% ROI- 52W High-74.51% Beta2.85
Dividend %- Quick Ratio3.00 Sales past 5Y-9.50% Gross Margin- 52W Low36.72% ATR2.37
Employees177 Current Ratio3.00 Sales Q/Q147.60% Oper. Margin- RSI (14)41.08 Volatility13.68% 13.73%
OptionableYes Debt/Eq0.34 EPS Q/Q9.60% Profit Margin- Rel Volume0.82 Prev Close18.29
ShortableYes LT Debt/Eq0.21 EarningsMay 09 AMC Payout- Avg Volume656.44K Price16.57
Recom2.70 SMA20-14.06% SMA50-27.76% SMA200-53.20% Volume538,206 Change-9.40%
May-11-22Upgrade Robert W. Baird Underperform → Neutral $21 → $18
Apr-21-22Downgrade Citigroup Buy → Neutral $86 → $29
Jan-31-22Upgrade Raymond James Underperform → Mkt Perform
Aug-12-21Downgrade Raymond James Mkt Perform → Underperform
Aug-11-21Downgrade Goldman Neutral → Sell $29
Aug-10-21Downgrade Robert W. Baird Neutral → Underperform $31
Jul-02-21Initiated Cantor Fitzgerald Overweight $71
Jun-25-21Resumed Goldman Neutral $29
Jun-21-21Downgrade Barclays Equal Weight → Underweight $33 → $25
Jun-04-21Resumed Robert W. Baird Neutral $31
Feb-17-21Downgrade B. Riley Securities Neutral → Sell
Jan-19-21Downgrade B. Riley Securities Buy → Neutral $138 → $77
Jan-15-21Downgrade B. Riley Securities Buy → Neutral $138 → $77
Jan-07-21Initiated Wells Fargo Overweight $118
Dec-29-20Downgrade Robert W. Baird Outperform → Neutral $79 → $69
Dec-29-20Downgrade Raymond James Outperform → Mkt Perform
Dec-29-20Downgrade H.C. Wainwright Buy → Neutral
Dec-29-20Downgrade Barclays Overweight → Equal Weight $46
Dec-23-20Downgrade ROTH Capital Buy → Sell $77
Dec-08-20Reiterated B. Riley Securities Buy $111 → $138
May-11-22 06:19AM  
May-09-22 05:15PM  
May-05-22 12:05PM  
May-04-22 04:39PM  
May-01-22 09:51AM  
Apr-27-22 08:00AM  
Apr-20-22 11:13AM  
Mar-25-22 09:49AM  
Mar-21-22 07:41AM  
Mar-18-22 08:00PM  
Mar-17-22 06:19AM  
Mar-14-22 08:00AM  
Mar-01-22 11:00AM  
Feb-28-22 05:15PM  
Feb-24-22 09:25AM  
Feb-21-22 03:00PM  
Feb-18-22 08:00PM  
Feb-16-22 08:00AM  
Feb-08-22 08:00AM  
Jan-31-22 04:40AM  
Jan-25-22 08:00AM  
Jan-24-22 09:23AM  
Jan-21-22 08:14PM  
Jan-18-22 07:00AM  
Dec-25-21 06:02AM  
Dec-24-21 12:38AM  
Dec-18-21 12:38AM  
Dec-17-21 08:00PM  
Dec-16-21 01:32PM  
Dec-13-21 08:00AM  
Dec-10-21 09:03AM  
Nov-22-21 08:00AM  
Nov-18-21 08:00PM  
Nov-10-21 04:20AM  
Nov-08-21 05:35PM  
Nov-01-21 03:01PM  
Oct-25-21 04:00PM  
Oct-21-21 08:00AM  
Oct-20-21 08:00PM  
Oct-19-21 05:55AM  
Oct-18-21 10:01AM  
Oct-15-21 02:30AM  
Oct-12-21 08:00AM  
Sep-29-21 02:35PM  
Sep-22-21 04:01PM  
Sep-08-21 09:00AM  
Sep-07-21 09:00AM  
Sep-05-21 06:55AM  
Aug-11-21 01:00PM  
Aug-09-21 05:25PM  
Aug-03-21 11:21AM  
Aug-02-21 03:01PM  
Jul-28-21 08:30AM  
Jul-26-21 04:01PM  
Jul-06-21 09:00AM  
Jul-05-21 02:04AM  
Jun-09-21 09:00AM  
Jun-02-21 09:01AM  
May-21-21 02:24AM  
May-13-21 06:10AM  
May-10-21 08:05PM  
May-03-21 08:30AM  
Apr-29-21 05:02PM  
Apr-14-21 01:36AM  
Apr-05-21 06:15AM  
Mar-30-21 08:30AM  
Mar-09-21 06:35AM  
Mar-01-21 05:26PM  
Feb-28-21 02:14AM  
Feb-22-21 08:00AM  
Feb-19-21 08:00AM  
Feb-11-21 08:30AM  
Jan-28-21 08:30AM  
Jan-23-21 04:40AM  
Jan-12-21 06:51AM  
Jan-07-21 03:19PM  
Jan-06-21 03:59PM  
Jan-05-21 08:57AM  
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chivukula PadChief Scientific Officer & COOJan 04Sale40.008,100324,000594,448Jan 06 04:01 PM
Chivukula PadChief Scientific Officer & COODec 16Sale40.003,633145,328602,548Dec 20 04:01 PM
Chivukula PadChief Scientific Officer & COODec 08Sale40.006,367254,680606,181Dec 10 04:01 PM
Chivukula PadChief Scientific Officer & COONov 01Sale44.4110,000444,100612,548Nov 03 11:20 AM
Chivukula PadChief Scientific Officer & COOOct 01Sale44.3610,000443,600622,548Oct 04 05:01 PM
Chivukula PadChief Scientific Officer & COOSep 01Sale55.8610,000558,600632,548Sep 02 09:06 PM
Ultragenyx Pharmaceutical Inc.DirectorAug 11Sale45.8375,0003,437,2501,400,000Aug 12 05:11 PM
Ultragenyx Pharmaceutical Inc.DirectorAug 10Sale55.44725,00040,194,0001,475,000Aug 12 05:11 PM
Chivukula PadChief Scientific Officer & COOAug 03Sale40.0710,000400,700642,548Aug 05 04:32 PM